Joint Clinical Trials Office

You are here

Biomarkers of attention impairment in Traumatic Brain Injury (TBI)

Clinical Trial Details

Impaired attention is the most common and most debilitating cognitive deficit following traumatic brain injury (TBI), leading to rehabilitation barriers and long-term disability. While recovery is sometimes observed both spontaneously, and with rehabilitation, there are more than 5.3 million persons in the US alone remaining with chronic cognitive dysfunction as a result of TBI. There are currently no targeted interventions and no reliable diagnostic/prognostic biomarkers. There is a critical need to elucidate the individual specific pathophysiology of attentional deficits following TBI. 

Study contact by location

Upper East Side - Manhattan


Ryan Lowder

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment